Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities

Summary We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the context of obesity and type 2 diabetes, may improve glycaemic control and weight‐related comorbidities, and in some cases, induce diabetes remission. Although lifestyle‐based weight loss strategies may be ini...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Obesity reviews 2019-06, Vol.20 (6), p.816-828
Hauptverfasser:	Brown, Emily, Wilding, John P.H., Barber, Thomas M., Alam, Uazman, Cuthbertson, Daniel J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Body weight Body weight gain Body weight loss Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Drug therapy Energy balance Epidemics GLP-1 receptor agonists Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glucose Glucose transporter Heterogeneity Humans Inhibitors Obesity Obesity - complications Obesity - drug therapy Pharmacology Remission SGLT2 inhibitors Sodium Sodium-Glucose Transporter 2 Inhibitors - therapeutic use type 2 diabetes Weight control Weight loss Weight Loss - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!